Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis (vol 23, pg 596, 2017)

被引：4
|
作者：
Kalincik, T.
Jokubaitis, V
Spelman, T.
机构：
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷 / 14期
关键词：
D O I：
10.1177/1352458517735739
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis (vol 72, pg 405, 2015)
    He, A.
    Spelman, T.
    Jokubaitis, V
    JAMA NEUROLOGY, 2015, 72 (08) : 950 - 950
  • [42] CLADRIBINE TREATMENT OF MULTIPLE-SCLEROSIS (VOL 344, PG 538, 1994)
    GRIEB
    LANCET, 1994, 344 (8929): : 1098 - 1098
  • [43] Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy
    Al-iedani, Oun
    Lea, Rodney
    Ribbons, Karen
    Ramadan, Saadallah
    Lechner-Scott, Jeannette
    JOURNAL OF NEUROIMAGING, 2022, 32 (06) : 1109 - 1120
  • [44] Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod
    Hoepner, Robert
    Havla, Joachim
    Eienbroeker, Christian
    Tackenberg, Bjoern
    Hellwig, Kerstin
    Meinl, Ingrid
    Hohlfeld, Reinhard
    Gold, Ralf
    Kuempfel, Tania
    Kleiter, Ingo
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (13) : 1714 - 1720
  • [45] Fingolimod/natalizumabReactivation of multiple sclerosis following natalizumab withdrawal: case report
    Reactions Weekly, 2013, 1433 (1) : 22 - 22
  • [46] Switching From Natalizumab to Fingolimod in Multiple Sclerosis A French Prospective Study
    Cohen, Mikael
    Maillart, Elisabeth
    Tourbah, Ayman
    De Seze, Jerome
    Vukusic, Sandra
    Brassat, David
    Anne, Olivier
    Wiertlewski, Sandrine
    Camu, William
    Courtois, Vie
    Ruet, Aurelie
    Debouverie, Marc
    Le Page, Emmanuelle
    Casez, Olivier
    Heinzlef, Olivier
    Stankoff, Bruno
    Bourre, Bertrand
    Castelnovo, Giovanni
    Rico, Audrey
    Berger, Eric
    Camdessanche, Jean-Philippe
    Defer, Gilles
    Clavelou, Pierre
    Al Khedr, Abdullatif
    Zephir, Helene
    Fromont, Agnes
    Papeix, Caroline
    Brochet, Bruno
    Pelletier, Jean
    Lebrun, Christine
    JAMA NEUROLOGY, 2014, 71 (04) : 436 - 441
  • [47] Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved Reply
    Cohen, Mikael
    Lebrun, Christine
    JAMA NEUROLOGY, 2014, 71 (07) : 925 - 925
  • [48] Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal
    Pinheiro, Bernardete
    Guerreiro, Rita
    Costa, Joao
    Miguel, Luis Silva
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 484 - 491
  • [49] Effect of Fingolimod and Interferon β-1α in Children With Multiple Sclerosis
    Zhao, Ying
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (01) : E99 - E101
  • [50] Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
    Cohen, Jeffrey A.
    Barkhof, Frederik
    Comi, Giancarlo
    Hartung, Hans-Peter
    Khatri, Bhupendra O.
    Montalban, Xavier
    Pelletier, Jean
    Capra, Ruggero
    Gallo, Paolo
    Izquierdo, Guillermo
    Tiel-Wilck, Klaus
    de Vera, Ana
    Jin, James
    Stites, Tracy
    Wu, Stacy
    Aradhye, Shreeram
    Kappos, Ludwig
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05): : 402 - 415
12345